Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04YJO
|
|||
| Former ID |
DIB011218
|
|||
| Drug Name |
CGS-19480A
|
|||
| Synonyms |
3-(Dipropylamino)-5-ethoxy-3,4-dihydro-2H-[1]-benzothiopyran hydrochloride
Click to Show/Hide
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Investigative | [1], [2] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Modulator | [1], [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | WO patent application no. 2012,0025,83, Method for treating schizophrenia and related diseases with a combination therapy. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.